Navigation Links
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
Date:5/14/2009

yle and B Levin (eds). "World Cancer Report 2008.", World Health Organization: International Agency for Research on Cancer. Lyon: 2008.
  • Martin, Lainie and Russell Schilder. "Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition" J Clin Oncol. 25, 2894-2901 (2007). Available at: http://jco.ascopubs.org/cgi/reprint/25/20/2894. Accessed on 5 May 2009.
  • Spannuth, W. A. et al. "Angiogenesis as a Strategic Target for Ovarian Cancer Therapy." Nature. 5, No.4. (2008). Available at: http://www.nature.com/nrclinonc/journal/v5/n4/pdf/ncponc1051.pdf. Accessed on 5 May 2009.
  • Kumaran, G. C. et al. "Minireview: Antiangiogenic Drugs in Ovarian Cancer." British J of Canc. 100, 1-7 (2009). Available at: http://www.nature.com/bjc/journal/v100/n1/pdf/6604767a.pdf. Accessed on 5 May 2009.
  • American Cancer Society. "Cancer Facts and Figures 2008." Atlanta: 2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed on 5 May 2009.
  • American Cancer Society. "Ovarian Cancer Detailed Guide." Atlanta: 2008. Available at: '/>"/>

  • SOURCE Boehringer Ingelheim
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
    2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
    3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
    4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
    5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
    8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
    9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
    10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
    11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
    (Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
    (Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
    Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
    ... Nov. 7, 2011 Inovio Pharmaceuticals, Inc. (NYSE AMEX: ... 30, 2011. Total revenue was $2.6 million and $8.2 ... compared to $1.3 million and $3.8 million for the same periods ... nine months ended September 30, 2011, were $9.0 million and $24.0 ...
    ... CHICAGO, Nov. 7, 2011 UCB today announced findings ... rates to Cimzia ® (certolizumab pegol) plus methotrexate ... effect on structural joint damage in patients with moderate ... responses were found by both RAPID3 (Routine Assessment of ...
    Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 2New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 3New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 4New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 5New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 6New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 7New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 8New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 10New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 11New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 12
    (Date:4/24/2014)... On April 28, the Center for BrainHealth will ... our most pressing brain-related challenges at its inaugural ... Resilience and Regeneration." Featured speakers will include Dr. ... the Center for BrainHealth, U.S. Senator Chuck Grassley ... Doggett, Deputy Assistant Secretary for Policy and Early ...
    (Date:4/24/2014)... Depression affects more than one out of three ... study released in The Lancet Respiratory Medicine ... symptoms physically rather than mentally. , It is ... mental health and functional outcomes of critical care ... assistant professor of Medicine, and it highlights a ...
    (Date:4/24/2014)... LA The National Science Foundation has awarded ... Experiences for Undergraduates (REU) Site grant in the ... training of undergraduates from diverse social and educational ... New Orleans area. The project will provide ... summers of 2014-16. It will be led ...
    (Date:4/23/2014)... immigrants from Sub-Saharan Africa, Latin America and Caribbean ... to new research from St. Michael,s Hospital. , ... Journal of Obstetrics and Gynaecology , assessed the ... and native-born women in six high-immigration countries ... and Valencia) and the United States (California, New ...
    (Date:4/23/2014)... 23, 2014 The American Society for Radiation Oncology ... of Postoperative Radiation Therapy for Endometrial Cancer: An ... adjuvant radiation therapy in the treatment of endometrial ... the May-June 2014 issue of Practical Radiation ... of ASTRO. The full-length guideline is available as ...
    Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
    ... use a new combination of the chemotherapy, Capecitabine, together ... have an 88 percent chance of surviving the cancer ... at the plenary session, October 3, 2011, at the ... Oncology (ASTRO). "The results of the trial allow ...
    ... released this week, challenges people to test their knowledge ... they learn about the complexities of the disease, which ... Californians. Developed as a free download by the ... and QuantiaMD, a company headquartered in Waltham, Massachusetts, the ...
    ... The University of North Carolina at Chapel Hill has ... Institute of Diabetes and Digestive and Kidney Diseases to ... Reduce Health Disparities (CDTR). Its mission is to reduce ... resources and support to foster translational research in North ...
    ... from Rhode Island Hospital researchers suggests that controlling cholesterol may ... non-steroidal anti-inflammatory drugs (NSAIDs) such as naproxen. The findings are ... in clinically relevant animal models when high cholesterol is a ... the journal Surgery . NSAIDs are among ...
    ... health challenges earlier than their fellow seniors, researchers ... lives of 8,700 older people, a Case Western ... reported physical limitations by African American women in ... finding surfaced as researchers looked generally at how ...
    ... the Witwatersrand goldfields, not far from bustling Johannesburg, South Africa, ... littered with mounds of waste and underlain by a deep ... with water. Today, the mines are producing less and less ... estimate the volume of acid mine drainage from abandoned mines ...
    Cached Medicine News:Health News:Chemo plus radiation before surgery increases tumor response for rectal cancer 2Health News:Interactive mobile app from UCSF and QuantiaMD teaches people how to manage diabetes 2Health News:Interactive mobile app from UCSF and QuantiaMD teaches people how to manage diabetes 3Health News:New UNC Center for Diabetes seeks to reduce health disparities 2Health News:New UNC Center for Diabetes seeks to reduce health disparities 3Health News:Rhode Island Hospital researchers find possible cardiovascular risk with NSAID use 2Health News:African-American women develop functional challenges earlier than others 2Health News:African-American women develop functional challenges earlier than others 3
    Inquire...
    ... a premium agarose used for isolating DNA ... produces clear sharp bands, with no smearing ... UltraClean Forensic Agarose is tested and certified ... activity and DNA contamination. Meets ...
    ... 1000 is specifically formulated for high resolution ... <1000 bp. This standard melting temperature agarose ... as 10 bp difference in size. ... gel structure for better handling and improved ...
    Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
    Medicine Products: